Media stories about Thermo Fisher Scientific (NYSE:TMO) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Thermo Fisher Scientific earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 46.820488706426 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment’s analysis:
- Thermo Fisher Scientific Prices Offering of Common Stock – PR Newswire (press release) (prnewswire.com)
- Thermo Fisher Scientific Advances Cryo-EM Leadership to Drive Structural Biology Discoveries (stl.news)
- Thermo Fisher Scientific Showcases Innovations in Electron Microscopy and Spectroscopy at M&M 2017 (markets.businessinsider.com)
- Thermo Fisher Scientific (TMO) Commences $1.5B Common Stock Offering (streetinsider.com)
- Thermo Fisher Scientific Improves Protein Research With Seven Steps (bio-medicine.org)
Several equities analysts have issued reports on the company. Jefferies Group LLC boosted their target price on Thermo Fisher Scientific from $160.00 to $175.00 and gave the stock a “hold” rating in a research report on Friday, April 28th. Deutsche Bank AG set a $200.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Saturday, June 10th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $200.00 target price (up previously from $195.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 13th. Cleveland Research raised Thermo Fisher Scientific from a “neutral” rating to a “buy” rating in a research note on Thursday, July 20th. Finally, Bank of America Corporation reaffirmed a “buy” rating and issued a $210.00 target price (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. One investment analyst has rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and an average target price of $188.56.
Shares of Thermo Fisher Scientific (NYSE TMO) traded down 0.42% during midday trading on Wednesday, hitting $173.26. 4,284,555 shares of the company’s stock were exchanged. The firm has a market cap of $67.57 billion, a price-to-earnings ratio of 30.18 and a beta of 1.06. Thermo Fisher Scientific has a 52 week low of $139.07 and a 52 week high of $182.87. The company has a 50-day moving average of $177.02 and a 200-day moving average of $164.40.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion during the quarter, compared to analysts’ expectations of $4.92 billion. During the same quarter in the prior year, the company posted $2.03 earnings per share. The firm’s revenue was up 10.2% on a year-over-year basis. Equities research analysts expect that Thermo Fisher Scientific will post $9.24 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.45%.
In related news, CEO Marc N. Casper sold 20,000 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the transaction, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at $46,528,718.41. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $176.26, for a total transaction of $440,650.00. Following the transaction, the chief financial officer now directly owns 37,790 shares in the company, valued at $6,660,865.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,188 shares of company stock valued at $4,702,223. 0.49% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the property of of Ticker Report. If you are reading this report on another publication, it was copied illegally and republished in violation of US and international trademark and copyright law. The original version of this report can be viewed at https://www.tickerreport.com/banking-finance/2795971/thermo-fisher-scientific-tmo-earning-somewhat-positive-media-coverage-report-finds.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.